Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Total darkness at night is key to success of breast cancer therapy -- Tulane study

25.07.2014

Exposure to light at night, which shuts off nighttime production of the hormone melatonin, renders breast cancer completely resistant to tamoxifen, a widely used breast cancer drug, says a new study by Tulane University School of Medicine cancer researchers.


Principal investigators and co-leaders of Tulane's Circadian Cancer Biology Group, Steven Hill (left) and David Blask (right), and team members Robert Dauchy and Shulin Xiang.

Credit: Photograph by Paula Burch-Celentano, Tulane University

The study, "Circadian and Melatonin Disruption by Exposure to Light at Night Drives Intrinsic Resistance to Tamoxifen Therapy in Breast Cancer," published in the journal Cancer Research, is the first to show that melatonin is vital to the success of tamoxifen in treating breast cancer.

Principal investigators and co-leaders of Tulane's Circadian Cancer Biology Group, Steven Hill and David Blask, along with team members Robert Dauchy and Shulin Xiang, investigated the role of melatonin on the effectiveness of tamoxifen in combating human breast cancer cells implanted in rats.

"In the first phase of the study, we kept animals in a daily light/dark cycle of 12 hours of light followed by 12 hours of total darkness (melatonin is elevated during the dark phase) for several weeks," says Hill. "In the second study, we exposed them to the same daily light/dark cycle; however, during the 12 hour dark phase, animals were exposed to extremely dim light at night (melatonin levels are suppressed), roughly equivalent to faint light coming under a door."

Melatonin by itself delayed the formation of tumors and significantly slowed their growth but tamoxifen caused a dramatic regression of tumors in animals with either high nighttime levels of melatonin during complete darkness or those receiving melatonin supplementation during dim light at night exposure.

These findings have potentially enormous implications for women being treated with tamoxifen and also regularly exposed to light at night due to sleep problems, working night shifts or exposed to light from computer and TV screens.

"High melatonin levels at night put breast cancer cells to 'sleep' by turning off key growth mechanisms. These cells are vulnerable to tamoxifen. But when the lights are on and melatonin is suppressed, breast cancer cells 'wake up' and ignore tamoxifen," Blask says.

The study could make light at night a new and serious risk factor for developing resistance to tamoxifen and other anticancer drugs and make the use of melatonin in combination with tamoxifen, administered at the optimal time of day or night, standard treatment for breast cancer patients.

Arthur Nead | Eurek Alert!
Further information:
http://www.tulane.edu

Further reports about: Biology Cancer Melatonin Tulane breast dark darkness night potentially sleep therapy tumors turning

More articles from Life Sciences:

nachricht Singapore researchers discover a gene that increases incidence of AML
22.09.2014 | National University of Singapore

nachricht The accelerator of molecular motors
22.09.2014 | Ruhr-University Bochum

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Anzeige

Anzeige

Event News

Future questions regarding data processing

22.09.2014 | Event News

"Start-ups and spin-offs funding – Public and private policies", 14th October 2014

12.09.2014 | Event News

BALTIC 2014: Baltic Sea Geologists meet in Warnemünde

03.09.2014 | Event News

 
Latest News

Siemens D3 wind turbines ordered for onshore project in France

22.09.2014 | Press release

Wireless Sensor Transmits Tumor Pressure

22.09.2014 | Medical Engineering

UChicago-Argonne National Lab Team Improves Solar-Cell Efficiency

22.09.2014 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>